1. Drug elimination in chronic liver diseases;Huet;J Hepatol,1997
2. FDA. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labelling. 2003. Disponible en: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
3. EMEA. Guideline on evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. Disponible en: http://www.emea.europa.eu/pdfs/human/ewp/233902en.pdf
4. Dosage adjustment for hepatic dysfunction based on Child-Pugh scores;Spray;Am J Health Syst Pharm,2007
5. Drug disposition in patients with HBsAg-positive chronic liver disease;Villeneuve;Dig Dis Sci,1987